One type of stock—dividend growers—outperforms all others as interest rates rise and to back it up Bloomberg and Goldman Sachs (GS) looked at the performance of 50 stocks the bank sees as likely to hike their payouts by an average of 12% this year. (I’ll reveal—and rank—the 4 strongest names from this list in just a moment.) Words: 1229
The comments above & below are edited ([ ]) and abridged (…) excerpts from the original article by Brett Owens (ContrarianOutlook.com)
The verdict? The “Goldman 50” beat the market between the end of June 2016 and March 21 of this year—a period that saw the Fed drop two quarter-point rate hikes on us – and it wasn’t even close.
- The dividend growers were up 10 points on the S&P 500 on March 21
- and on March 15, they were up 11.9%, the widest spread in any 8.5-month period since the financial crisis.
Well, knock me over with a feather. Fact is, Goldman and Bloomberg didn’t have to cobble together 50 stocks to tell us dividend-growth addicts what we already know:
- dividend growers are practically guaranteed to outperform—not only when the Fed sends rates up, but in all market weather.
There’s already a pile of research that says so. Like the study from ETF provider Realty Shares…which…produced data starting way back on January 31, 1972 and ending where Goldman/Bloomberg pick up: at the end of June 2016. The findings? See for yourself:
None of this is to say that what Goldman and Bloomberg have done is a waste of time—far from it. By targeting stocks expected to hike their payouts double-digits, on average, this year, they’ve handed us a nice jumping-off point to start searching for the next great dividend growers.
Now it’s up to us to take things further—and I’m going to do just that, grinding down the list with five filters I use to find top-quality dividend-growth stocks every day.
- A respectable dividend yield: I want to see a dividend yield that at least beats the 1.9% the average S&P 500 stock pays (and the higher the better), so we’ll set our bar at around 2.3%.
- A reasonable payout ratio, or the percentage of trailing-twelve month earnings that went out to investors as dividends. I demand a ratio of 50% at most.
- A strong history of earnings and sales growth.
- A price-to-earnings ratio below that of the market.
- Manageable debt, which is key to keeping payouts popping higher as rates do the same.
After running the Goldman 50 through that obstacle course, I’ve narrowed the list to four. Going from here to a buy decision, though, is still a big leap, so let’s dive deeper and rank these survivors, starting with:
WHR: Cheap … but for Good Reason
Whirlpool (WHR) is certainly cheap, trading at 14.9 times trailing-twelve-month earnings, but that’s because there are plenty of things that could trip up the appliance maker in the next few months.
- One is the fact that it gets more than half its revenue from outside the U.S., so the strong greenback—which would get stronger with rising rates—is a headache. In 2016, Whirlpool posted 2% revenue growth in constant currency, but exchange rates kept sales flat.
- I think first-level investors are making too much of the impact a collapse of Sears Holdings (SHLD) could have on Whirlpool. But Sears still has about 20% of the US appliance market, so Whirlpool would take a hit, at least until growing retailers like Home Depot (HD) pick up the slack. Sales would also get squeezed if rate hikes kneecap the housing market.
- Meantime, revenue is already starting to plateau:
The company’s payout ratio is just 33%, second lowest of our group, so the dividend is safe, but these risks could certainly weigh on payout growth and, with a yield of just 2.3%, we’re not exactly getting a bucket of cash to wait around and see what happens.
Which brings me to:
A High-Paying Sin Stock With a Big Catch
Altria Group (MO) is proof that as much as folks love to complain about smoking, they’re more than happy to own cigarette stocks – and that’s because it pays off. MO has been on a steady burn in the past five years, more than doubling up the market when you factor in dividends:
It’s the dividend growth that’s gotten investors hooked: the company has boosted its payout by 49% since 2012. It’s also the kingpin of our “Goldman 5” in the yield department, at 3.3% so why isn’t it further up my list?
- It looks cheap, with a trailing-twelve-month P/E ratio of 10.0 but that’s because its earnings per share (EPS) were juiced by a big one-time gain on the sale of SABMiller to Anheuser-Busch InBev last year (Altria held 27% of SABMiller and now has a 10.5% stake in the merged brewer).
- On a forward basis, its P/E of 22.4 is well above its five-year average and the market’s ratio of 18.3: That rich valuation is keeping me from hitting the buy button, because there are better deals available…
The Runner-Up: Interpublic Group
Interpublic Group (IPG) yields 2.9%—below Altria—but its payout has been on a much stronger growth tear, having tripled in the past five years. That’s come as the explosive growth of digital marketing has driven the advertising giant’s revenue higher. Check out how IPG’s surging payout has lit up its share price:
Right away, you’ll see that the stock takes a nice jump up with every payout boost … except the last two. That tells me IPG’s stock is due to catch up, and there are two things that could be the trigger:
- a ridiculously low valuation. Right now, IPG trades at 16.8 times trailing-twelve-month earnings, below its five-year average of 17.2 and the S&P 500. That’s way too cheap for a company that’s posted incredible EPS growth since the financial crisis:
- and management’s share buybacks. in the last six years, IPG has taken 20% of its shares off the market, boosting EPS and helping its share price rise ever higher and management isn’t stopping, with the board recently clearing it to buy back another $300 million worth of shares, which is roughly what it spent last year. With the stock looking cheap and more growth ahead, the timing couldn’t be better.
Interpublic would be my favorite, if not for another stock with even faster dividend growth…
The Champ: Amgen
- Amgen (AMGN)’s payout is on fire, surging 219% in the past five years;
- the payout ratio is a miniscule 38.9%
- revenue and EPS have been, well, off the charts:
- The balance sheet also gets a clean bill of health, with long-term debt of $34.6 billion that’s more than canceled out by Amgen’s $38.1-billion cash hoard.
- Finally, Amgen is cheap, with a P/E ratio of 15.9, compared to a five-year average of 18.3.
The company is in the doghouse after test results from its Repatha cholesterol drug disappointed investors, especially in light of its hefty $14,000 yearly price tag, but Amgen goes a lot further than just one drug.
- Its pipeline boasts 12 treatments in Phase III trials;
- its massive cash hoard sets it up for a big acquisition;
- it spends a high 17% of its revenue on R&D; and
- its current drugs delivered a decent 5% sales boost in 2016.
- The Street has an average 12-month price target of $187 on the stock, despite the Repatha disappointment, which would translate into a 15% gain from today’s level.
Win An iPad Pro!